← board
PRTCY
distress 1/10 · well-funded / low risk$16.70-2%today-16% from 52w high
Revenue
pre-revenue
Liquidity
$277M
Runway
3.3 yrs
Shares 1y
0%
Price & events
-12.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-1.9%
1W
-3.4%
1M
-6.0%
3M
-9.9%
6M
-10.0%
1Y
-25.8%
2Y
-65.2%
5Y
-70.4%
All
Overview
- Market Cap
- $4.04B
- Enterprise Value
- $3.78B
- Volume
- 100
- 52 Week Range
- $14.50 – $19.84
- Total Shares
- 241.68M
- Float Shares
- 15.73M
- Short %
- 0.12%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.57%
- RVOL
- 0.07x
- Beta
- 0.79
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-27earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 241,684,038 · 0 offerings/1y · 0 PIPEs
- 2024-07-09SC 13D/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.